CA-MANSCAPED-INC
21.7.2021 15:02:12 CEST | Business Wire | Press release
You ready to rock the landscaped look? Let’s get mowin’. Today, MANSCAPED™ , the global leader and category creator of men’s below-the-waist grooming, announces the international launch of its fourth-generation electric trimmer, The Lawn Mower® 4.0 . Designed and engineered specifically for groin and body grooming, the brand’s newest masterpiece focuses on intelligent functionality, maximum performance and, of course, a superior below-the-waist grooming experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005277/en/
What’s more, The Lawn Mower 4.0 has been integrated into MANSCAPED’s thoughtfully curated bundles for the ultimate self-care routine. The hotly anticipated device and newly elevated kits are now shipping to the United Kingdom , the European Union , Norway , Switzerland , Australia , and New Zealand , in addition to the United States and Canada.
“The global launch of The Lawn Mower 4.0 and our newest packages means getting our latest and most exciting innovations into the hands of millions of men all over the world,” said Paul Tran, Founder and CEO of MANSCAPED. “It’s milestones like these that further advance our vision of driving the movement that changes the face of male grooming — something we’re both humbled by and proud to do every day and with every launch.”
What can you expect with the latest and greatest debuting from the global grooming giant? We’re glad you asked...
The Lawn Mower® 4.0 Groin Trimmer
Proven product attributes and state-of-the-art upgrades come together to make this tool the marquee groin and body trimmer on the market.
Core Features:
- SkinSafe® technology to help reduce the risk of nicks, snags, and tugs
- Powerful 7,000 RPM motor with QuietStroke™ technology
- Rechargeable 600 mAh li-ion battery
- Waterproof design for convenient wet or dry operation
New Enhancements:
- Wireless charging system with electromagnetic induction
- 4000k LED spotlight with diffuser so you can see where you’re trimming
- Cutting-edge ceramic blade to help reduce grooming accidents
- Adjustable trimming guard sizes 1 to 4, with 3, 6, 10, or 13mm settings
- Modern two-toned black finish and powerful packaging presentation
- Travel lock for safety - and racking up frequent flier miles
To up-level your grooming game, or give the greatest gift ever, consider exploring MANSCAPED’s luxury kits that combine The Lawn Mower 4.0 with an array of other top-selling tools, formulations, and accessories. When used together, cleanliness and confidence are abounding.
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver® Ball Deodorant - Avoid stenchy under regions and the dreaded “swamp crotch”; infused with cooling aloe vera, this formulation helps combat sweat and unwanted odor down there
- Crop Reviver® Ball Toner - This spray is the solution for maintaining hygiene and freshness, especially when on-the-go; relieve high-friction areas and post-shave irritation with just a spritz
- This bundle’s free gifts include The Shed premium travel bag and the much acclaimed MANSCAPED™ Boxers made with a microfiber blend
Add another essential men's grooming tool into the mix with this kit featuring MANSCAPED’s premier above-the-waist tool.
- The Weed Whacker® Nose & Ear Hair Trimmer - MANSCAPED redesigned the traditional nose hair taming device by focusing on the highest performance and comfort; equipped with SkinSafe technology, a 9,000 RPM motor, and 360-degree rotary dual-blade system
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver Ball Deodorant
- Crop Reviver Ball Toner
- The Shed & MANSCAPED Boxers
To learn more and to purchase any of these new products or packages, visit MANSCAPED.com, a one-stop-shop destination website designed for customers in the United Kingdom, European Union, Norway, Switzerland, Australia, New Zealand, Canada and more regions to come this year.
About MANSCAPED™:
Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist, trusted by over 2 million men worldwide. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target, Best Buy, and Macy’s stores throughout the U.S. and Hairhouse locations in Australia. For more information, visit the website or follow on Facebook , Instagram , Twitter , TikTok , YouTube , and Triller.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom